Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future.
Welcome to our first update of 2022. The run up to the tax year end is always a busy time and this year has been no different. Our investment team has completed two exits, three investments and are building up a considerable pipeline for Q2.
As popularity for VCTs across the board has continued to grow this has led to record capital inflows. This looks set to increase year on year, with pension contributions tightening and an increase in dividend tax rates, investors look to alternative asset classes for returns. We are delighted that investors are supportive of venture capital and the UK’s early stage ecosystem.
The Calculus VCT now holds 35 companies and we are aiming to increase this to 40 companies in the next quarter. We have a healthy pipeline and are undergoing due diligence for a number of deals.
Our EIS Fund is now in its 23rd year and we continue to make growth focused investments into the technology, healthcare and creative industries.
If you would like to get in touch with our Investor Relations team to discuss your current portfolio or about making a new investment, they would be very happy to assist; 0207 493 4940/ [email protected]
Best wishes,
John Glencross
Calculus Capital News
0% Initial Fee until 05 April – Limited Capacity
Calculus VCT’s next allotment is 05 April and the deadline for applications is 04 April 4pm.
– Target annual dividend of 4.5% of NAV has consistently been met
– Minimum Investment amount £5,000
– Buyback scheme at 5% discount to NAV available after 5 years
– Dividend reinvestment scheme and monthly standing order available
Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future.
Learn more about Calculus VCT here
Calculus EIS Fund’s next tranche close is 29 April 2022. The Fund offers an opportunity to invest in entrepreneurial businesses with growth potential, across the fastest growing sectors in the UK – technology, healthcare and creative.
Learn more about our EIS Fund here
We are hiring
The Calculus team is growing and we are hiring for two new positions. Please follow the links to find the job specs and details on how to apply.
Portfolio Highlights
Wonderhood Studios releases Devil’s Advocate
Wonderhood released the Devil’s Advocate: The Mostly True Story of Giovanni Di Stefano, on Sky and NowTV. The documentary tells the unbelievable story of one of the most famous lawyers in the UK, defending warlords and serial killers such as Saddam Hussein and Harold Shipman. However he was a conman with no legal qualifications.
Arecor granted key U.S. patent protecting proprietary insulin products, which could revolutionise the lives of diabetics
The new patent is a key milestone and has applications for multi dose compositions, particularly in injection pen formats.
Invizius announced major grant to bring haemodialysis treatment to clinic
The biotech company that develops treatments to suppress unwanted innate immune responses announced a £1m grant to bring H-Guard, its proprietary priming solution to reduce inflammatory effects of haemodialysis, to the clinic.
Maze Theory exited for 1.3x return
Maze Theory shares held by Calculus Capital EIS Funds and the Calculus VCT plc have been purchased by a strategic investor, Pluto Digital.
Past performance is not indicative of future performance.
eConsult wins contract with Homerton Emergency Department to help reduce waiting times
eConsult have won a contract to implement their eTriage system in Homerton Emergency Department to enable an electronic check-in service.
New Investments
Calculus invests into Destiny Pharma
The company is developing novel antimicrobial drugs for infection control.
Calculus backs MIP Diagnostics with further funding
MIP Diagnostics, a UK nanotechnology business has secured increased investment of its previous round of funding, totalling £7.3M.
Investor Relations
For more information about any of our funds or to speak to a member of the team please get in touch.
